Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because cannabis is still a schedule 1 drug in the U.S.,

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

CannaTech

JANUARY 16, 2019

Pharmaceutical grade cannabis is relatively new in parts of the world. The availability of medications for patients varies from country to condition. These estimates vary drastically source to source, which reflects what conditions make a patient eligible for a cannabis-based medicine.

Access 89

Access Patients Pharmaceutical Education 89

Cannabis Law Report

JUNE 1, 2022

This acquisition will accelerate Khiron’s growth in Europe by controlling the complete value chain for its products and gaining direct access to German pharmacies. Pharmadrug GmbH has been active worldwide for almost 40 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients.

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

Cannabis Law Report

SEPTEMBER 29, 2022

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy. The Therapeutic Goods Administration (TGA) issued 73 infringement notices totalling $972,360 between the medicinal cannabis companies MGC Pharmaceuticals Ltd, Cannatrek Ltd and Little Green Pharma Ltd.

Epilepsy 52

Epilepsy Conditions Media Medicine 52

SpeedWeed

APRIL 9, 2021

Although this survey is specifically focused on Texas’ medical marijuana program, it also supports other research showing that cannabis can serve as an effective replacement for pharmaceuticals. The post 61% of Medical Cannabis Users in Texas Said Weed Helped Them Get off Pharmaceuticals appeared first on SpeedWeed.

Pharmaceutical 52

Pharmaceutical Chronic Pain Programs Patients 52

Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Unfortunately, this number is expected to increase rapidly with legalized marijuana and access to substances that have five times the THC concentration of regular marijuana,” said Mr. Allen. “We About Anebulo Pharmaceuticals, Inc. and Australia.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

SEPTEMBER 22, 2021

Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Under the terms of the agreement OCT will use reasonable efforts to develop and commercialise: (i) at least one CBD derivative; (ii) at least one CBG derivative; and (iii) at least one THC derivative, as pharmaceutical drug products.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Canna Care Docs

NOVEMBER 4, 2024

Patients dealing with chronic pain from numerous conditions are finding relief in cannabis. Healthcare, tennis player and injured black man or athlete with muscle pain or inflammation after exercise or workout Chronic Pain and Challenges Chronic pain is a long-lasting condition that persists for more than 3-6 months, sometimes lasting years.

Chronic Pain 111

Chronic Pain Nerve Pain Treatment Cannabinoids 111

NORML

MAY 26, 2020

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain.

Clinical Trials 245

Clinical Trials Chronic Pain Cannabinoids Patients 245

Cannabis Law Report

DECEMBER 8, 2021

Global Psychiatry Partnering 2014 to 2021 provides the full collection of Psychiatry disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Access to headline, upfront, milestone and royalty data. Access to hundreds of Psychiatry deal contract documents. Accera Pharmaceuticals.

Access 52

Access Data Pharmaceutical Research and Development 52

Cannabis Law Report

JULY 5, 2021

Access Control. Since the ERP is equipped with all of the company’s information, the access to data is controlled. and each user can only access part of the information. The QA department usually defines the user access to be controlled and each user will have his. Some users can have unique privileges to.

Pharmaceutical 111

Pharmaceutical Data Access Business 111

Veriheal

JULY 26, 2023

Georgia medical cannabis patients will soon have greater access to treatment as cannabis oil will be sold in many more pharmacies. Eligible patients were granted access to low-THC marijuana oil. Andrew Turnage, the executive director of the Georgia Access to Medical Cannabis Commission, spoke on this fact.

Oil 98

Oil Patients Access THC 98

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions. Image by Pfüderi from Pixabay.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

JANUARY 6, 2022

Oregon’s developing psilocybin program is nothing short of revolutionary and provides an opportunity to investigate the potential of psilocybin in treating a myriad of mental health conditions. An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. info@gl-lg.com ? or 503-488-5424.

Access 52

Access Patients Research and Development Treatment 52

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. The live webcast can be accessed here and on the investor page of Marinus’ website. The condition is caused by inherited mutations in either the TSC1 gene or the TSC2 gene. About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. Epidyolex has been approved as a treatment option for children as young as two with Lennox-Gastaut syndrome or Dravet syndrome – difficult-to-treat conditions that can cause multiple seizures a day. ” Source BBC: [link].

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

LifeCannMD

AUGUST 30, 2024

Fernando Fandiño-Sende , who is double board certified in Cardiology and Internal Medicine, will educate you about the benefits of Medical Marijuana according to your qualifying conditions. Florida’s legalization of medical marijuana in 2016 marked a significant shift in how patients manage chronic conditions.

Marijuana 52

Marijuana Chronic Pain Treatment Pharmaceutical 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because cannabis is still a schedule 1 drug in the U.S.,

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

MGC Pharma

FEBRUARY 22, 2018

of respondents who received Medical Cannabis treatment reported improvement in their condition and significant reductions to pain levels. An increasing number of older people are seeking the treatment for conditions such as inflammatory arthritis, autoimmune disease and chronic pain. namely Australia’s aging population.

Research and Development 100

Research and Development Pharmaceutical Chronic Pain Treatment 100

Veriheal

SEPTEMBER 27, 2021

The United Kingdom’s Multiple Sclerosis (MS) Society has taken a stand against restricted access to medical cannabis in the country. Medical cannabis has been legal in the nation for almost three years—so why are MS patients struggling to access the treatment? Yet many people with MS are still unable to access it.”

Treatment 98

Treatment Patients Access Research and Development 98

LifeCannMD

NOVEMBER 24, 2023

Our patients get a medical marijuana card for various reasons, primarily related to the potential medical benefits of using marijuana for various health conditions. The primary reason our patients choose to get their Medical Marijuana card is to manage symptoms and improve the quality of life for individuals with specific medical conditions.

Marijuana 52

Marijuana Chronic Pain Conditions Patients 52

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Accessed July 25, 2021. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

NewsMunchies

JULY 10, 2023

With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds major potential to increase the accessibility of drugs and to treat diseases and conditions. AI automation opens up the possibility of faster, cheaper pharmaceuticals.

Treatment 58

Treatment Research and Development Pharmaceutical Microdosing 58

MMJ Recs

FEBRUARY 3, 2024

This guide aims to navigate the intricate web of cannabis legislation in Philadelphia, Pennsylvania, exploring key aspects such as medical marijuana laws, cannabis regulations, qualifying conditions, patient eligibility, and the overall impact on the local cannabis industry.

Legislation 52

Legislation Law Marijuana Dispensary 52

The Cannigma

JUNE 25, 2022

Poland established a medical cannabis program in 2017, which allows for a range of cannabis products to be prescribed for a range of medical conditions. Patients must have a doctor’s prescription as well as permission from a regional pharmaceutical inspector to obtain cannabis products. Poland and cannabis. Can you grow your own weed?

Legalization 112

Legalization Supply Chain Chronic Pain Tincture 112

Cannabis Law Report

JUNE 5, 2021

Why does Argentina have the conditions to be an important producer in the cannabis and hemp industry? According to Kulfas, the benefits will include: Health rights: supply of medical cannabis to ensure better access to health. ley cáñamo argentina. Employment: Generation of quality jobs. Exports: Potential foreign exchange generation.

Hemp 105

Hemp Research and Development Pharmaceutical Agriculture 105

Cannabis Law Report

JULY 21, 2022

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Kabir Nath as Chief Executive Officer, effective August 1, 2022. London, UK July 19, 2022.

Therapy 52

Therapy Research and Development Pharmaceutical Patients 52

Veriheal

OCTOBER 13, 2020

Ulcerative Colitis is a condition that causes long-lasting inflammation and ulcers (sores) in the innermost lining of the individual’s large intestine and rectum. Crohn’s Disease is also a condition that causes inflammation, but it affects the lining of the digestive tract, which can then spread deeply into the affected tissues. .

Digestion 123

Digestion Treatment Conditions Research and Development 123

Cannabis Law Report

JANUARY 4, 2022

With the conditional approval, ADCL can immediately employ the Linea 2.0 With the conditional approval, ADCL can immediately employ the Linea 2.0 Hayward, president and CEO of Applied DNA, stated, “We are grateful to the NYSDOH for conditional approval of our Linea 2.0 Assay (the “Linea 2.0 The Linea 2.0 Dr. James A.

Conditions 52

Conditions Research and Development Therapy Supply Chain 52

NORML

JANUARY 24, 2019

It seeks to redefine allowed dosage limitations and formulations, and expand patient access and reduce patient cost by adding nurse practitioners and physician assistants to the list of those authorized to issue written certifications to patients.

Policy 158

Policy Patients Education Legislation 158

Cannabis Law Report

OCTOBER 26, 2021

Following this selection, Tilray will supply a variety of its pharmaceutical-grade medical cannabis products, including extracts and dried flower with different degrees of THC and CBD for patients with varying medical conditions.

Pharmaceutical 52

Pharmaceutical Research and Development Patients Access 52